Ms. Buckley has successfully represented companies in obtaining HCPCS, CPT, and ICD-10-CM diagnosis codes, as well as Medicare Part B Transitional Pass-through Payment Status under the Hospital Outpatient Prospective Payment System. She also has assisted companies in developing strategies for mitigating coverage challenges, as well as technical coding and payment policy issues.
Prior to joining Kimbell & Associates, Ms. Buckley led the U.S. federal health policy portfolio and served as a federal lobbyist for MedImmune, a biotechnology company that is now part of AstraZeneca. Before joining MedImmune, Ms. Buckley practiced law for many years in the Healthcare Regulatory practice group at Sidley Austin LLP. She began her career as an associate in the Washington, D.C. office of DLA Piper.